Behavioral counseling and abstinence-contingent take-home buprenorphine in general practitioners' offices in Malaysia: a randomized, open-label clinical trial.
Richard S SchottenfeldMarek C ChawarskiMahmud MazlanPublished in: Addiction (Abingdon, England) (2021)
Providing opioid-dependent patients in Muar, Malaysia with buprenorphine-naloxone and physician management plus behavioral counseling or abstinence-contingent buprenorphine-naloxone (ACB) resulted in greater reductions of opioid use compared with providing buprenorphine-naloxone and physician management without behavioral counseling or ACB.
Keyphrases
- smoking cessation
- clinical trial
- open label
- end stage renal disease
- primary care
- emergency department
- ejection fraction
- hiv testing
- newly diagnosed
- chronic kidney disease
- phase ii
- healthcare
- peritoneal dialysis
- prognostic factors
- pain management
- phase iii
- randomized controlled trial
- men who have sex with men
- patient reported outcomes
- phase ii study
- human immunodeficiency virus